Interactive presentation

Answers to Commonly Asked Questions in Alzheimer’s Disease

Dr. Scott Turner answers questions submitted by participants of the activity title “Moving Forward in Alzheimer’s Disease: New Management Paradigms for Patients and Healthcare Systems.” Topics include therapeutic targets, selecting patients for biomarker tests, treatment initiation, practice and infrastructure changes with disease-modifying therapies, and the future of AD treatment.
Suggested Readings

The future of anti-amyloid trials.

Aisen PS, Cummings J, Doody R, et al. J Prev Alzheimers Dis. 2020;7(3):146-151.

2021 Alzheimer’s disease facts and figures.

Alzheimer’s Association.

Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need.

Babulal GM, Quiroz YT, Albensi BC, et al. Alzheimers Dement. 2019;15(2):292-312.

Neuropathological stageing of Alzheimer-related changes.

Braak H, Braak E. Acta Neuropathol. 1991;82(4):239-259.

EMERGE and ENGAGE topline results: two phase 3 studies to evaluate aducanumab in patients with early Alzheimer’s disease.

Budd Haeberlein S, von Hehn C, Tian Y, et al. Presented at: 12th Clinical Trials on Alzheimer’s Disease; December 4-7, 2019; San Diego, CA.

Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias.

Chételat G, Arbizu J, Barthel H, et al. Lancet Neurol. 2020;19(11):951-962.

Biomarkers for Alzheimer's disease. Where we stand and where we are headed.

Chrem Méndez P, Surace E, Bérgamo Y, et al. Medicina (B Aires). 2019;79(Spec 6/1):546-551.

Imaging and molecular mechanisms of Alzheimer's disease: a review.

Femminella GD, Thayanandan T, Calsolaro V, et al. Int J Mol Sci. 2018;19(12):3702.

Costly new Alzheimer disease medications on the horizon—financing alternatives for Medicare.

Fleming WK, Brown CR, Shrank WH. JAMA Health Forum. 2020;1(9):e201148.

Dose- and time- dependent changes in plasma p-tau181 in patients treated with aducanumab in the ENGAGE and EMERGE trials

Hanson O, Nisenbaum L, Chen T, et al. Presented at: 14th Clinical Trials on Alzheimer’s Disease; November 9-12, 2021; virtual conference.

Pharmacotherapy of Alzheimer's disease: seeking clarity in a time of uncertainty.

Husna Ibrahim N, Yahaya MF, Mohamed W, et al. Front Pharmacol. 2020;11:261.

Donanemab in early Alzheimer's disease.

Mintun MA, Lo AC, Duggan Evans C, et al. N Engl J Med. 2021;384(18):1691-1704.

High performance plasma amyloid-β biomarkers for Alzheimer's disease.

Nakamura A, Kaneko N, Villemagne VL, et al. Nature. 2018;554(7691):249-254.

Increasing precision of clinical diagnosis of Alzheimer's disease using a combined algorithm incorporating clinical and novel biomarker data.

Sabbagh MN, Lue LF, Fayard D, Shi J. Neurol Ther. 2017;6(suppl 1):83-95.

Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease.

Salloway S, Chalkias S, Barkhof F, et al. JAMA Neurol. 2022;79(1):13-21.

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.

Swanson CJ, Zhang Y, Dhadda S, et al. Alzheimers Res Ther. 2021;13(1):80.

Potential new approaches for diagnosis of Alzheimer’s disease and related dementias.

Turner RS, Stubbs T, Davies DA, Albensi BC. Front Neurol. 2020;11:496.

What are the difficulties of implementing innovative pharmacy practice models in the care of patients with dementia?

Wimo A. Expert Rev Pharmacoecon Outcomes Res. 2021;21(1):1-4.

Economic burden of Alzheimer disease and managed care considerations.

Wong W. Am J Manag Care. 2020;26(suppl 8):S177-S183.

Related activities
SnapShot 
0.25 CME/CE

Pathophysiology of Alzheimer's Disease

Module 1

Faculty: Sharon Cohen, MD; R. Scott Turner, MD, PhD
Release: 02/17/2022
Expiration: 02/17/2023
SnapShot 
0.25 CME/CE

Evaluation and Diagnosis of MCI and AD

Module 2

Faculty: Sharon Cohen, MD; R. Scott Turner, MD, PhD
Release: 02/17/2022
Expiration: 02/17/2023
SnapShot 
0.25 CME/CE

Management of AD

Module 3

Faculty: Sharon Cohen, MD; R. Scott Turner, MD, PhD
Release: 02/17/2022
Expiration: 02/17/2023
SnapShot 
0.25 CME/CE

Barriers to Optimizing Alzheimer's Disease Management

Module 4

Faculty: Sharon Cohen, MD; R. Scott Turner, MD, PhD
Release: 02/17/2022
Expiration: 02/17/2023